This 1994 review analyzed 20 English-language studies from 1967 to March 1993, focusing on the impact of pharmacologic therapy lasting ≥6 months on weight loss and maintenance. Agents studied included phentermine, mazindol, fenfluramine, dexfenfluramine, and fluoxetine. While initial weight loss varied across studies, a plateau or weight regain was commonly
This 2002 randomized, double-blind study evaluated weight changes over 26–32 weeks in 284 patients with major depressive disorder treated with fluoxetine, sertraline, or paroxetine. Paroxetine-treated patients experienced a significant average weight gain of 3.6%, with 25.5% gaining more than 7% of their baseline weight. In contrast, fluoxetine-treated patients had a
This study investigates the antidepressant-like effects of cannabidiol (CBD) in mice, highlighting its role in serotonin modulation. Administering 10 mg/kg of CBD induced significant antidepressant effects in the forced swim test (FST), comparable to fluoxetine (10 mg/kg) and desipramine (5 mg/kg). Lower doses of CBD (7 mg/kg) combined with sub-effective
